The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs: a Swedish nationwide study (COVID-19-REUMA)

The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs: a Swedish nationwide study (COVID-19-REUMA)

ABSTRACTStudies investigating the immunogenicity of additional COVID-19 vaccine doses in immunosuppressed patients with inflammatory rheumatic diseases (IRD) are still limited. The objective was to explore the antibody response including response to omicron virus subvariants (sBA.1 and sBS.2) after...

Full description

Bibliographic Details
Main Authors: Martina Frodlund, Per Nived, Katerina Chatzidionysiou, Anna Södergren, Eva Klingberg, Monica Hansson, Sophie Ohlsson, Elisa Pin, Anders Bengtsson, Lars Klareskog, Meliha Kapetanovic
Format: Article
Language:English
Published: American Society for Microbiology 2024-04-01
Series:Microbiology Spectrum
Subjects:
COVID-19 vaccine
serological response
biological/targeted DMARDs
response rate
omicron subvariants
immunogenicity
Online Access:https://journals.asm.org/doi/10.1128/spectrum.02981-23

Similar Items

Similar Items